TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00772967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultracet
Description: Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultracet
Description: Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultracet
Description: Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultracet
Description: Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultracet
Description: Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultracet
Description: Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Study: NCT04298346

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02238613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radioactive stent
Description: radioactive stent carrying seed iodine 125

Intervention type: DEVICE
Group type: OTHER
Intervention: plastic stent
Description: common plastic stent without carrying seed iodine 125
Study: NCT01483404

Intervention type: PROCEDURE
Intervention: Measurement with O2c
Description: Intra-surgery measurement of the microcirculation with the O2c device
Study: NCT01362322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix TM (new syringe presentation)
Description: Single dose, intramuscular administration in a new syringe presentation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix TM (previous syringe presentation)
Description: Single dose, intramuscular administration in previous syringe presentation
Study: NCT02552407

Intervention type: DEVICE
Intervention: Manual Aspiration Thrombectomy
Description: Thrombus aspiration
Study: NCT02993302

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: patients were given PTU and placebos
Study: NCT01698008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Doctor Mobile app
Description: Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
Study: NCT03709589

Intervention type: OTHER
Intervention: Modified Early Warning Score
Description: Modified Early Warning Score

Intervention type: OTHER
Intervention: Modified Early Warning Score
Description: Modified Early Warning Score
Study: NCT02567292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Milk
Description: Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants \<37 weeks PMA and/or or weight \<2,200g or PBCLN-002 for infants \>37 weeks PMA and/or weight \>2,200g)
Study: NCT03436420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Participants will take 300 milligrams (mg) of gemcabene, once per day for 12 weeks.
Study: NCT01159353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
Study: NCT04574700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knee joint mobilization and traction
Description: Grade 3 traction (Kaltenborn)from knee fully flexed to end of available Range of motion(ROM). Traction 30 sec, 10 sec rest period, 4reps, total 2 min of traction.3 sets for a total of 6 min of traction mobilization.Grade3 keltonborn tibiofemoral and tibiofibular anterior, posterior mobilization 3 sets10glides/set, 3 times/week on alternative days for 4 weeks.~TENS for 20 mins in sitting and strengthening exercises i.e. Quadriceps Setting10 reps, air Cycling 2 min for a bout, straight leg raise (SLR) with weight , Full arc extension 10 reps of each exercise will be carried per session except for full-arc extension and air cycling. Air cycling cont. for 2 min for 1 bout of exercise. Measurement will be taken at base level, after first and last session. Treatment will be given for 3 times/week on alternative days for 4 weeks
Study: NCT03733145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Participants in the ACE inhibitors, ARBs, and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.
Study: NCT04711187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 Formulation 1
Description: AT-527 Formulation 1 (R07496998)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 Formulation 1
Description: AT-527 Formulation 1 (R07496998)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo Comparator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo Comparator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo Comparator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 Formulation 2
Description: AT-527 Formulation 2 (R07496998)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 Formulation 2
Description: AT-527 Formulation 2 (R07496998)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 Formulation 2
Description: AT-527 Formulation 2 (R07496998)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 Formulation 2
Description: AT-527 Formulation 2 (R07496998)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 Formulation 2
Description: AT-527 Formulation 2 (R07496998)
Study: NCT03944746

Intervention type: OTHER
Intervention: Education Curriculum
Description: Different educational curriculums were applied to each cohort

Intervention type: OTHER
Intervention: Education Curriculum
Description: Different educational curriculums were applied to each cohort
Study: NCT02055547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 175μg
Description: Single dose 175μg SC injection in a treatment period (Part 1, Panel B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 175μg
Description: Single dose 175μg SC injection in a treatment period (Part 1, Panel B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 175μg
Description: Single dose 175μg SC injection in a treatment period (Part 1, Panel B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 200μg
Description: Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)
Study: NCT04574700

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post isometric relaxation
Description: Control group include Post isometric relaxation technique on hamstring muscle will be performed in supine lying, hip flexed to 90 degrees knee extended until the point of resistance 20% of maximum effort will be used by patient to create isometric contraction. Patient will be asked to breathe in and hold for 5 to 8 seconds and release both breath and effort then move to new barrier point and process was repeated three times per session~TENS and strengthening exercises as mentioned above.~This treatment regime will be given for 3 times/week on alternative days for 4 weeks.
Study: NCT00003812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00215553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A.1 Lucinactant
Description: 3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
Study: NCT02055547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 200μg
Description: Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 200μg
Description: Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 300μg
Description: Single dose 300μg SC injection in a treatment period (Part 1, Panel A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 300μg
Description: Single dose 300μg SC injection in a treatment period (Part 1, Panel A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 50/72μg
Description: MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 72/125μg
Description: MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 100/150μg
Description: MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125/150μg
Description: MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
Study: NCT00215553

Intervention type: OTHER
Group type: OTHER
Intervention: B.3 SoC
Description: Standard ARDS management and ICU care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A.2 Lucinactant
Description: 3 30 mL aliquots at a concentration of 10 mg/mL each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A.3 Lucinactant
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A.4 Lucinactant
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B.1 Lucinactant
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B.2 Lucinactant
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
Study: NCT01189890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Glimepiride
Description: Matching placebo tablets to glimepiride to allow for blinding.
Study: NCT03198793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001
Description: Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]) over 8 weeks.
Study: NCT03356561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 5*10^10 vp
Description: Participants will receive Ad26.ZIKV.001 at a dose of 5\*10\^10 vp via IM route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 5*10^10 vp
Description: Participants will receive Ad26.ZIKV.001 at a dose of 5\*10\^10 vp via IM route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 1*10^11 vp
Description: Participants will receive Ad26.ZIKV.001 at a dose of 1\*10\^11 vp via IM route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 1*10^11 vp
Description: Participants will receive Ad26.ZIKV.001 at a dose of 1\*10\^11 vp via IM route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo via IM route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo via IM route.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo via IM route.
Study: NCT03719937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: weight on the anterior chest of the patient
Description: The investigators aim at assessing whether and to what extent an artificial increase in chest wall elastance, while the patient is in the supine position, may yield a significant benefit to oxygenation. The increase in chest wall elastance will be will be achieved placing a 100 g/kg weight on the anterior chest wall of the patient while he/she is in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
Study: NCT00981175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis virus, then ChimeriVax diluent
Description: ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax diluent, then Live attenuated Japanese encephalitis virus
Description: ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.
Study: NCT03591536

Intervention type: OTHER
Group type: OTHER
Intervention: Pentoxifylline
Description: 400 mg pentoxifylline oral tablet from 3 days before surgery and on the day of surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo tablets from 3 days before surgery and on the day of surgery
Study: NCT02217553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
Study: NCT02924116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioboosti
Description: Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioboosti
Description: Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioboosti
Description: Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
Study: NCT04200209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a quality indicator feedback mechanism
Description: 1. Audit and feedback: A summary of clinical performance and hospital safety culture over a specified period of time.~2. Benchmarking Achievable: benchmarks are calculated from the performance of all members of a peer group and represents a realistic standard of excellence attained by the top performers in that group (i.e. comparing to the top 10% of peers).~3. Educational outreach: A trained independent person or investigator will meet with health professionals or managers in their practice setting to provide information (e.g. feedback of quality indicators).~4. Action planning: The purpose of action planning is to support quality improvement efforts by identifying opportunities for improvement, strategies and steps to accomplish the work.
Study: NCT02357277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: inhaled glucocorticoid budesonide as dry powder inhaler
Study: NCT03250195

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/MRI
Description: PET/MRI scan
Study: NCT02326246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi-parametic MRI
Study: NCT02011997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patients undergo cVATS segmentectomy
Study: NCT02055547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
Study: NCT02011997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients undergo cVATS lobectomy
Study: NCT03098901

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tc99m-labeled pyrophosphate scan
Description: Intravenous injection of Tc99m-labeled pyrophosphate with consecutive whole body scan using gamma ray scanner for assessment of radioactive uptake in the heart. The results of the scan will be evaluated by a specialist in the field. The uptake will be graded using Perugini scale (0- no uptake, 1- uptake in heart less intense than in bones, 2-uptake in heart as intense as in bones, 3-uptake in heart more intense than in bones).
Study: NCT02427763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hours of use (Essix)
Description: the patient will use de thermoplastic device during the night or during all day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hours of use (Essix)
Description: the patient will use de thermoplastic device during the night or during all day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collect saliva
Description: the patient spit during 30 seconds in a small bottle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collect saliva
Description: the patient spit during 30 seconds in a small bottle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collect biofilm
Description: a sterile swab is rubbed at the buccal surface of the upper teeth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collect biofilm
Description: a sterile swab is rubbed at the buccal surface of the upper teeth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collect epithelium
Description: a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collect epithelium
Description: a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch